PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (CIK: 0001003124) EDGAR, Information, Filings... CompaniesBIO.Com

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

Mailing address
929 NORTH FRONT STREET, WILMINGTON, North Carolina, 28401
Phone
9102510081
State location
North Carolina
State of incorporation
North Carolina
Fiscal year end
December 31
SIC
8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Filings
N/A

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (CIK: 0001003124) is an American company incorporated in the state of North Carolina. Head office is located at 929 NORTH FRONT STREET, WILMINGTON, North Carolina, 28401. Work in the industry 8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC is a public company and trade via Over-The-Counter (OTC).

Old names:

PHARMACEUTICAL PRODUCT DEVELOPMENT INC from 1996-15-May to 2014-18-Feb

Owner	Filings	Transaction Date	Type of Owner
Hill Raymond H	0001529930	Sep-16-2011	director, officer: Chief Executive Officer
SNYDERMAN RALPH	0001178031	May-18-2011	director
BRYSON VAUGHN D	0001189539	May-18-2011	director
INGRAM ROBERT ALEXANDER	0001219890	May-18-2011	director
COLVIN PAUL	0001513900	Feb-23-2011	officer: EVP - Clinical Development
Babiss Lee	0001498376	Oct-01-2010	officer: Exec. VP - Global Lab Services
Dingivan Christine A	0001440766	Jul-28-2008	officer: EVP/Chief Medical Officer
Wilkinson Michael O.	0001431373	Apr-01-2008	officer: Executive Vice President
Darazsdi Daniel G	0001412292	Oct-01-2007	officer: Chief Financial Officer
Sharbaugh William J	0001399883	May-31-2007	officer: Chief Operating Officer
BADDOUR LINDA	0001181151	May-18-2007	officer: Former Chief Financial Officer
Wilkinson Peter J	0001398138	Apr-26-2007	officer: VP Finance/Chief Acct. Officer
Richardson William W	0001343084	Nov-01-2005	officer: Sr. VP Global Business Dev.
Casieri Francis J	0001300892	Aug-16-2004	officer: Sr. VP, Global Bus. Dev.
FOX MARYE ANNE	0001180603	May-19-2004	director
BONDURANT STUART	0001181152	May-19-2004	director
FRANK FRED	0001181155	May-19-2004	director
KLEMA CATHY	0001181157	May-19-2004	director
MAGNUSON TERRY	0001181158	May-19-2004	director
SHANNON COLIN	0001285101	May-17-2004	officer: COO--Europe
MARIO ERNEST	0001180469	Dec-31-2003	director
DAVENPORT FRED B JR	0001181154	Dec-03-2003	officer: President
HARTMAN JUDD	0001181156	Dec-03-2003	officer: General Counsel
GRANGE DAVID L	0001264908	Oct-15-2003	director
COVINGTON PAUL S	0001181153	Jun-30-2003	officer: Executive Vice President
STAUB W RICHARD	0001181162	Jun-30-2003	officer: Sr. Vice President
MCNEILL JOHN A JR	0001033408	Jun-19-2003	director
ESHELMAN FREDRIC N	0001033409	Jun-17-2003	director, 10 percent owner, officer: Chief Executive Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950157-24-000416 (34 Act) Size: 0 KB	Mar-14-2024	001-39727 24750563
3/A	Document	Amendment to Initial statement of beneficial ownership of securities Acc-no: 0001628280-21-022213 (34 Act) Size: KB	Nov-08-2021	001-39727 211387992
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001628280-21-020187 (34 Act) Size: 0 KB	Oct-18-2021	001-39727 211328706
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-18-048806 (34 Act) Size: 0 KB	Aug-01-2018	001-38601 18985713
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001104659-18-047104 (34 Act) Size: 0 KB	Jul-25-2018	001-38601 18969883
CT ORDER	Document	Acc-no: 9999999997-14-001000 (34 Act) Size: KB	Feb-18-2014	000-27570 14620552
CT ORDER	Document	Acc-no: 9999999997-13-017300 (34 Act) Size: KB	Dec-16-2013	000-27570 131278123
15-12G	Document	Notice of termination of registration of a class of securities under Section 12(g) Acc-no: 0001193125-11-341802 (34 Act) Size: KB	Dec-15-2011	000-27570 111262589
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331954 (33 Act) Size: KB	Dec-06-2011	333-80691 111245684
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331941 (33 Act) Size: KB	Dec-06-2011	333-39974 111245658
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331940 (33 Act) Size: KB	Dec-06-2011	333-20925 111245657
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331939 (33 Act) Size: KB	Dec-06-2011	333-28435 111245656
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331937 (33 Act) Size: KB	Dec-06-2011	333-33760 111245649
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331936 (33 Act) Size: KB	Dec-06-2011	333-107005 111245646
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331932 (33 Act) Size: KB	Dec-06-2011	333-135731 111245643
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-11-331929 (33 Act) Size: KB	Dec-06-2011	333-159439 111245642
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001529930-11-000003 ( Act) Size: 0 KB	Dec-06-2011
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001178031-11-000006 ( Act) Size: 0 KB	Dec-06-2011
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001399883-11-000004 ( Act) Size: 0 KB	Dec-06-2011
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001343084-11-000004 ( Act) Size: 0 KB	Dec-06-2011

Recent 20 filings. View all PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC overview
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC job
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC stock
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC ownership
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC CEO
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.